HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy era

Journal of Clinical Oncology

Volumn 30, Issue 33, 2012, Pages 4111-4116

  Montoto, Silvia ^a   Shaw, Kate ^b   Okosun, Jessica ^c   Gandhi, Shreyans ^d   Fields, Paul ^e   Wilson, Andrew ^a   Shanyinde, Milensu ^g   Cwynarski, Kate ^c   Marcus, Robert ^d   De Vos, Johannes ^a   Young, Anna Marie ^b   Tenant Flowers, Melinda ^d   Orkin, Chloe ^f   Johnson, Margaret ^c   Chilton, Daniella ^e   Gribben, John G ^a   Bower, Mark ^b  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^c ROYAL FREE HOSPITAL   (United Kingdom)

^d KING S COLLEGE HOSPITAL   (United Kingdom)

^e GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^f BARTS HEALTH NHS TRUST   (United Kingdom)

^g UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; BLEOMYCIN; DACARBAZINE; DOXORUBICIN; VINBLASTINE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CLASSICAL HODGKIN LYMPHOMA; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BLEOMYCIN; DACARBAZINE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HIV INFECTIONS; HODGKIN DISEASE; HUMANS; LYMPHOMA, AIDS-RELATED; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VINBLASTINE; YOUNG ADULT;

EID: 84869433391     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.41.4193     Document Type: Article

References (31)

1. Engels EA, Biggar RJ, Hall HI, et al: Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer 123:187-194, 2008
2. Shiels MS, Cole SR, Kirk GD, et al: A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals. J Acquir Immune Defic Syndr 52:611-622, 2009
3. Biggar RJ, Chaturvedi AK, Goedert JJ, et al: AIDS-related cancer and severity of immunosuppression in persons with AIDS. J Natl Cancer Inst 99:962-972, 2007
4. Biggar RJ, Jaffe ES, Goedert JJ, et al: Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. Blood 108:3786-3791, 2006
5. Herida M, Mary-Krause M, Kaphan R, et al: Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. J Clin Oncol 21:3447-3453, 2003
6. International Collaboration on HIV and Cancer: Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst 92:1823-1830, 2000
7. Bedimo R, Chen RY, Accortt NA, et al: Trends in AIDS-defining and non-AIDS-defining malignancies among HIV-infected patients: 1989-2002. Clin Infect Dis 39:1380-1384, 2004
8. Seaberg EC, Wiley D, Martinez-Maza O, et al: Cancer incidence in the multicenter AIDS Cohort Study before and during the HAART era: 1984 to 2007. Cancer 116:5507-5516, 2010
9. Bonnet F, Lewden C, May T, et al: Malignancy-related causes of death in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy. Cancer 101:317-324, 2004
10. Navarro JT, Lloveras N, Ribera JM, et al: The prognosis of HIV-infected patients with diffuse large B-cell lymphoma treated with chemotherapy and highly active antiretroviral therapy is similar to that of HIV-negative patients receiving chemotherapy. Haematologica 90:704-706, 2005
11. Oriol A, Ribera JM, Bergua J, et al: High-dose chemotherapy and immunotherapy in adult Burkitt lymphoma: Comparison of results in human immunodeficiency virus-infected and noninfected patients. Cancer 113:117-125, 2008
12. Gazzard BG, Anderson J, Babiker A, et al: British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med 9:563-608, 2008
13. Bower M, McCall-Peat N, Ryan N, et al: Protease inhibitors potentiate chemotherapy-induced neutropenia. Blood 104:2943-2946, 2004
14. Swerdlow SH, Campo E, Harris NL, et al: WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. Lyon, France, IARC Press, 2008
15. Santoro A, Bonadonna G, Valagussa P, et al: Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: Superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol 5:27-37, 1987
16. Cheson BD, Horning SJ, Coiffier B, et al: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas: NCI Sponsored International Working Group. J Clin Oncol 17:1244, 1999
17. Cheson BD, Pfistner B, Juweid ME, et al: Revised response criteria for malignant lymphoma. J Clin Oncol 25:579-586, 2007
18. Lanoy E, Rosenberg PS, Fily F, et al: HIV-associated Hodgkin lymphoma during the first months on combination antiretroviral therapy. Blood 118:44-49, 2011
19. Re A, Casari S, Cattaneo C, et al: Hodgkin disease developing in patients infected by human immunodeficiency virus results in clinical features and a prognosis similar to those in patients with human immunodeficiency virus-related non-Hodgkin lymphoma. Cancer 92:2739-2745, 2001
20. Hasenclever D, Diehl V: A prognostic score for advanced Hodgkin's disease: International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 339:1506-1514, 1998
21. Spina M, Gabarre J, Rossi G, et al: Stanford V regimen and concomitant HAART in 59 patients with Hodgkin disease and HIV infection. Blood 100:1984-1988, 2002
22. Xicoy B, Ribera JM, Miralles P, et al: Limited prognostic value of the International Prognostic Score in advanced stage human immunodeficiency virus infection-related Hodgkin lymphoma treated with the doxorubicin, bleomycin, vinblastine, and dacarbazine regimen. Leuk Lymphoma 50:1718-1720, 2009
23. Xicoy B, Ribera JM, Miralles P, et al: Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin's lymphoma. Haematologica 92:191-198, 2007
24. Hartmann P, Rehwald U, Salzberger B, et al: BEACOPP therapeutic regimen for patients with Hodgkin's disease and HIV infection. Ann Oncol 14:1562-1569, 2003
25. Hentrich M, Berger M, Hoffmann C, et al: HIV-related Hodgkin's lymphoma (HIV-HL): Results of prospective multicenter trial. Haematologica 96:s2, 2011 (abstr 519)
26. Mounier N, Spina M, Gabarre J, et al: AIDS-related non-Hodgkin lymphoma: Final analysis of 485 patients treated with risk-adapted intensive chemotherapy. Blood 107:3832-3840, 2006
27. Bower M, Collins S, Cottrill C, et al: British HIV Association guidelines for HIV-associated malignancies 2008. HIV Med 9:336-388, 2008
28. Montoto S, Wilson J, Shaw K, et al: Excellent immunological recovery following CODOX-M/IVAC, an effective intensive chemotherapy for HIV-associated Burkitt's lymphoma. AIDS 24:851-856, 2010
29. Rubinstein PG, Braik T, Jain S, et al: Ritonavir based highly active retroviral therapy (HAART) correlates with early neurotoxicity when combined with ABVD treated HIV associated Hodgkin lymphoma but not Non-Hodgkin lymphoma: A retrospective study. Blood 116:2807, 2010 (abstr)
30. Little RF, Pittaluga S, Grant N, et al: Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: Impact of antiretroviral therapy suspension and tumor biology. Blood 101:4653-4659, 2003
31. Hentrich M, Maretta L, Chow KU, et al: Highly active antiretroviral therapy (HAART) improves survival in HIV-associated Hodgkin's disease: Results of a multicenter study. Ann Oncol 17:914-919, 2006